Modulating UNC-51-like kinase 1 (ULK1) to treat diseases: A perspective from autophagic initiator to druggable target
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.117692 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Xinyi Qi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University,…. Hauptthemen laut MEDLINE: Autophagy-Related Protein-1 Homolog, Autophagy, Intracellular Signaling Peptides and Proteins, Protein Kinase Inhibitors. Die Arbeit nennt 106 Literaturangaben. Gefördert von: Southwest Jiaotong University, National Natural Science Foundation of China, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
UNC-51-like kinase 1 (ULK1), a serine/threonine kinase, serves as the master initiator of autophagy. By integrating upstream signaling pathways such as AMPK/mTOR, ULK1 orchestrates autophagosome formation while also participating in non-canonical functions including energy metabolism and immune regulation. In this review, we systematically delineate the molecular structure and biological functions of ULK1, while elucidating its intricate associations with human diseases. Furthermore, we comprehensively discuss current advances in small-molecule ULK1 activators and inhibitors, with particular emphasis on their combinatorial therapeutic strategies. This synthesis provides novel perspectives for developing ULK1-targeted pharmacological interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China; Institute of Precision Drug Innovation and Can…
Förderung
- Southwest Jiaotong University
- National Natural Science Foundation of China
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Qi, X., Fu, X., Wang, H., & Fu, L. (2026). Modulating UNC-51-like kinase 1 (ULK1) to treat diseases: A perspective from autophagic initiator to druggable target. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.117692
Vancouver
Qi X, Fu X, Wang H, Fu L. Modulating UNC-51-like kinase 1 (ULK1) to treat diseases: A perspective from autophagic initiator to druggable target. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.117692
BibTeX
@article{Qi2026,
author = {Qi, Xinyi and Fu, Xiangyu and Wang, Huiping and Fu, Leilei},
title = {Modulating UNC-51-like kinase 1 (ULK1) to treat diseases: A perspective from autophagic initiator to druggable target},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.117692}
}
EUVIMED